Table III.
Proportion of APB-positive cells after siRNA treatment
| Cell lines | siRNA treatmenta | APB+/SV40T−b (%) |
| IIICF-T/B3 | SV40T + C | 98/170 (57.6) |
| IIICF-402DE/D2 | SV40T + C | 20/176 (11.4) |
| IIICF-T/B3 | SV40T + p21-7 | 43/172 (25.0) |
| IIICF-402DE/D2 | SV40T + p21-7 | 18/179 (10.1) |
| JFCF-6/T.1J/1D | SV40T + C | 85/137 (62.0) |
| JFCF-6/T.1J/1D | SV40T + p21-6 | 36/132 (27.3) |
| IIICF-T/B3 | SV40T + C | 87/156 (55.8) |
| IIICF-T/B3 | SV40T + p21-6 | 34/158 (21.5) |
| IIICF-T/B3 | SV40T + p21-7 | 38/151 (25.2) |
| IIICF-T/B3 | SV40T + p53-9 | 29/153 (19.0) |
| IIICF-T/B3 | SV40T + p53-p | 38/160 (23.8) |
| IIICF-T/B3 | SV40T + PCNA-1 | 81/154 (52.6) |
| IIICF-T/B3 | SV40T + PCNA-6 | 82/149 (55.0) |
C, nonsilencing control siRNA.
a
Cells were treated with 10 nM siRNA per target for 4 d before being fixed for immunostaining.
b
Only cells that were negative by immunostaining for SV40T were examined for APBs.